http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Peter Senter ) 전남대학교 약품개발연구소 2015 약품개발연구지 Vol.24 No.-
He leads Seattle Genetics`` chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dama-Farber Cancer Institute, Harvard Medical School. Dr. Senter received an A.B. in Biochemistry from the University of California, Berkeley, a Ph.D. in Chemistry from the University of Illinois. and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Gottingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics (published by the American Association of Cancer Research) and serves as an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 140 scientific publications and holds more than 50 patents.